Which type of early breast cancer is Kisqali (ribociclib) approved to treat with an aromatase inhibitor?

Kisqali (ribociclib) with an aromatase inhibitor is approved for adjuvant treatment of hormone receptor-positive, HER2-negative early breast cancer at high risk of recurrence; pre- or perimenopausal women and men also require an LHRH agonist.